Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;2(1):76-85.
doi: 10.7150/thno.3462. Epub 2012 Jan 1.

Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors

Affiliations

Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors

Mulan Li et al. Theranostics. 2012.

Abstract

Purpose: This study was performed to compare the cytotoxicity and magnetic resonance (MR) contrast in diverse cultured cells and xenograft tumors models of two ultra-small superparamagnetic iron oxides (USPIOs), thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPION) and monocrystalline iron oxide nanoparticles (MION-47).

Materials and methods: Transmission electron microscopy (TEM) images and R(2) relaxivity values of the TCL-SPION and MION-47 were obtained and the cell viability and cell growth velocity of treated and untreated human fibroblasts and human umbilical vein endothelial cells (HUVEC) were evaluated. The effect of TCL-SPION and MION-47 on the secretion of interlukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), the production of nitric oxides and the mitochondrial membrane potentials in murine macrophage cells (RAW264.7) was compared. Human hepatocellular carcinoma cells (HepG2, 5x10(5)) were subcutaneously injected into nude mice (BALB/c) and in vivo MR imaging of tumors before and after injection with TCL-SPION or MION-47 (12.5 mg Fe/kg) was performed on a 1.5 Tesla MRI scanner.

Results: On TEM images, the average core diameter of TCL-SPION was 9 nm whereas that of MION-47 was 5 nm. TCL- SPION (345.0 ± 6.2 mM(-1)sec(-1)) had higher relaxivity (R(2)) than MION-47 (130.7 ± 1.1 mM(-1)sec(-1)). Significant changes in cell viability and growth were not found in human fibroblasts and HUVEC exposed to TCL-SPION and MION-47. However, IL-6 and TNF-α secretions increased dose-dependently and significantly in the macrophages treated with MION-47 or TCL-SPION. TCL-SPION had a lower stimulatory effect on IL-6 secretions than did MION-47 (P <0.05) and nitric oxides were produced in the macrophages by MION-47 but not TCL-SPION. A change in the mitochondrial membrane potential of the macrophages was observed 24 hours after the exposure, and MION-47 induced more collapses of the mitochondrial membrane potential than did TCL-SPION. In the in vivo MR imaging, 33.0 ± 1.3% and 7.5 ± 0.4% signal intensity decrease on T(2)*-weighted images was observed in the tumors injected with TCL-SPION and MION-47, respectively.

Conclusion: Due to the modified surface properties and larger core size of its iron oxide nanoparticles, TCL-SPION achieves lower cytotoxicity and better tumor MR contrast than MION-47. Our study suggests that TCL-SPION may be used as a new platform for tumor imaging and therapy monitoring.

Keywords: MION-47; Magnetic resonance imaging; TCL-SPION; Tumor targeting.; Ultra-small superparamagnetic iron oxides.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1
Physicochemical parameters and comparison of magnetic properties. (A) A schematic representation of TCL-SPION and MION-47. (B) TEM image of TCL-SPION and MION-47. (C) A T2-weighted MR image of TCL-SPION and MION-47 at various iron oxide concentrations. At identical iron oxide concentrations, TCL-SPION had a more intense MR contrast effect than MION-47. (D) Plots of the R2 (1/T2) value. The relaxivity (R2) of TCL-SPION (345.0 ± 6.2 mM-1sec-1, blue) was higher than that of MION-47 (130.7 ± 1.1 mM-1sec-1, red).
Figure 2
Figure 2
In vitro evaluation of cytotoxicity in human normal cells. (A, B) The viabilities of human fibroblasts and human umbilical vein endothelial cells (HUVEC) were assessed by MTT assay. A reduction in the viability of human fibroblasts and HUVEC was not observed after 24 hours of exposure to increasing concentrations of TCL-SPION and MION-47 (up to 1 mg Fe/mL). (C, D) The growth velocity was assessed by a trypan blue assay. The human fibroblasts and HUVEC were exposed to 100 µg Fe/mL of TCL-SPION or MION-47 separately for 3 days, and there was no effect on the cell growth velocity. The data are presented as the means ± standard errors from at least three independent experiments.
Figure 3
Figure 3
In vitro evaluation of cytokines release and nitric oxide production in macrophage. The levels of (A) IL-6 and (B) TNF-α released from mouse macrophage cells (RAW264.7). RAW264.7 cells were treated with TCL-SPION or MION-47 at concentrations of 25 µg Fe/mL and 50 µg Fe/mL for 24 hours. The IL-6 and TNF-α releases in the RAW264.7 cells were dose-dependently and significantly increased by adding TCL-SPION and MION-47 (*, P < 0.001, vs. control). MION-47 showed a greater stimulatory effect on IL-6 release than did TCL-SPION, while the TNF-α stimulatory effect was similar. (C) Nitric oxide production in macrophages. Macrophages were treated TCL-SPION or MION-47 at concentrations of 25 µg Fe/mL, 50 µg Fe/mL and 100 µg Fe/mL for 24 hours. The nitrite levels were assayed by the Griess reaction. MION-47 induced a dose-dependent and significant increase in nitric oxide production (*, P < 0.001, vs. control), but TCL-SPION did not have any stimulatory effect on nitric oxide production. All data are presented as the means ± standard errors from at least three independent experiments.
Figure 4
Figure 4
Mitochondrial membrane potential of macrophage. (A) Flow cytometry analysis of JC-1 in macrophages. Macrophages were treated with TCL-SPION or MION-47 at a concentration of 50 µg Fe/mL for 6 hours and 24 hours. The TCL-SPION and MION-47 treatments gradually reduced the population of healthy cells (the JC-1 aggregates). (*, P < 0.05, vs. control) (B) Fluorescence image of JC-1 aggregates (red) and JC-1 monomers (green) in macrophages. The MION-47 treated cells emitted more green fluorescence than did the TCL-SPION treated cells. All data are presented as the means ± standard errors from at least three independent experiments.
Figure 5
Figure 5
In vivo MR imaging. (A) T2*-weighted images of tumor-bearing mice injected with 12.5 mg Fe/kg of TCL-SPION or MION-47. After injection with TCL-SPION, a noticeable darkening appeared in the tumor area, indicating a large accumulation of TCL-SPION within the tumor. In the mice injected with MION-47, there was no considerable difference in the pre-injection and post-injection tumor signal intensities. (B) The changes in signal intensity measured on T2*-weighted tumor images. The tumor signal intensity of the mice injected with TCL-SPION was decreased by 33.0 ± 1.3%. MION-47 did not cause a significant change in signal intensity after injection (7.5 ± 0.4%). (C) Prussian blue staining of tumor microsections. More TCL-SPION was accumulated in the tumors than MION-47. All data are presented as the means ± standard errors from at least three independent experiments.

Similar articles

Cited by

References

    1. Benderbous S, Corot C, Jacobs P, Bonnemain B. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol. 1996;3(Suppl 2):S292–4. - PubMed
    1. Huang P, Li Z, Lin J, Yang D, Gao G, Xu C, Bao L, Zhang CL, Wang K, Song H, Hu HY, Cui DX. Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials. 2011;32:3447–58. - PubMed
    1. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002;9(Suppl 2):S304–6. - PubMed
    1. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19:311–30. - PubMed
    1. Leite FP TD, Vanduffel W, Fize D, Sasaki Y, Wald LL, Dale AM, Kwong KK, Orban GA, Rosen BR, Tootell RB, Mandeville JB. Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla. Neuroimage. 2002;16:283–294. - PubMed